^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SPP1-L

    i
    Other names: SPP1, Secreted Phosphoprotein 1, Osteopontin, Early T-Lymphocyte Activation 1, Urinary Stone Protein, Nephropontin, Uropontin, BNSP, OPN, Secreted Phosphoprotein 1 (Osteopontin, Bone Sialoprotein I, Early T-Lymphocyte Activation 1), Osteopontin/Immunoglobulin Alpha 1 Heavy Chain Constant Region Fusion Protein, Secreted Phosphoprotein 1 Variant 6, SPP1/CALPHA1 Fusion, Bone Sialoprotein 1, Bone Sialoprotein I, ETA-1, SPP-1, BSPI
    Entrez ID:
    6696
    Related biomarkers:
    Mutation
    Others
    12ms
    Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. (PubMed, Target Oncol)
    Low baseline plasma concentrations of HGF and IL-8 may predict better DCR and PFS in patients with mCRC receiving FTD/TPI plus bevacizumab, however further studies are warranted.
    P2/3 data • Journal • Metastases
    |
    IL6 (Interleukin 6) • HGF (Hepatocyte growth factor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SPP1 (Secreted Phosphoprotein 1) • THBS2 (Thrombospondin 2)
    |
    HGF-L • IL6-L • CXCL8-L • SPP1-L
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    1year
    SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer. (PubMed, Hum Genomics)
    Our study shows that the SPP1 gene might be an effective biomarker for predicting the prognosis and the efficacy of immunotherapy in PSCC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • CD4 expression • SPP1-L
    1year
    Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis. (PubMed, Cancers (Basel))
    Furthermore, the expression of SPP1 was found to be positively correlated with a number of immune checkpoint genes such as PD-1 and CTLA4. The current investigation indicates that the SPP1 protein could serve as a prognostic biomarker and merit further investigation to validate its clinical usefulness in patients with bladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-1 (Programmed cell death 1) • SPP1 (Secreted Phosphoprotein 1)
    |
    SPP1-L
    over1year
    HOXC8 mediates osteopontin expression in gastric cancer cells. (PubMed, J Cancer)
    Survival analysis demonstrated a decrease in overall survival rates among the high HOXC8/high SPP1 expression group compared with the low HOXC8/low SPP1 expression group. In conclusion, HOXC8 may be an independent prognostic factor and serve as a useful predictive biomarker for gastric cancer.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • HOXC8 (Homeobox C8)
    |
    SPP1-L
    almost2years
    Single-cell RNA Sequencing Reveals Distinct Populations of Tumor Associated Macrophages in Colorectal Metastasis. (SSO 2023)
    Deconvolution of CRC metastasis at a single-cell resolution deepens our understanding of functional heterogeneity of TAMs and their variable expression patterns in hematogenous and peritoneal metastases. Our findings may partially explain the differences in the tumor biology, treatment response, and clinical outcomes between CPM and HM.
    Clinical
    |
    SPP1 (Secreted Phosphoprotein 1) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    SPP1-L
    3years
    Attenuation of the Apoptosis Stimulating Protein of TP53-1 (ASPP1) Is a Predictive Marker for Therapy Resistance and Overall Survival in Acute Myeloid Leukemia (AML) (ASH 2021)
    As expected, cells were more chemo-susceptible when exposed to decitabine followed by daunorubicin and cytarabine in an ASPP1-dependent manner: MOLM-14.ASPP1i cell line strains did not reveal a significant change of proapoptotic efficacy when compared to mock strains which significantly benefitted from this approach with more than doubled proapoptotic rates (**** p < 0.0001, t-test), again confirming ASPP1 target specificity. Prospective clinical studies are warranted to evaluate the role as a biomarker for risk stratification. Further, we provide a rationale to re-sensitize high-risk patients (defined as ASPP1 low-expressors) towards chemotherapy using HMA priming upfront – and this strategy should be followed in future trials.
    Clinical
    |
    TP53 (Tumor protein P53)
    |
    SPP1-L • SPP1-H
    |
    cytarabine • decitabine • daunorubicin
    over3years
    The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis. (PubMed, Front Oncol)
    Furthermore, we found that the SPP1 expression was positively correlated with CD276, especially in patients with EGFR mutation. SPP1 levels might be a useful marker of immunosuppression in patients with EGFR mutation, and could offer insight for therapeutics.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • SPP1 (Secreted Phosphoprotein 1)
    |
    PD-L1 expression • EGFR mutation • EGFR expression • SPP1-L • SPP1-H